ANALYST-DOWNGRADE filed Jul 21, 2026 at 12:40 ET
Leerink Partners double-downgraded Gilead Sciences from Outperform to Market Perform on July 21, slashing its price target to $127 from $146, implying 4.7% downside from the current $133.21. The downgrade is a contrarian call against a heavily bullish consensus, 81% of analysts rate GILD Buy/Strong Buy, with a mean target of $158.30 (19% upside). Leerink's accuracy is below average at 49% on 257 calls, and its average return of 4.3% trails top-tier firms like RBC Capital (93% accuracy, 14.9% return). Recent insider selling by the CEO and other executives in July, totaling ~$3M, aligns with the bearish analyst action. However, institutional buying remains strong, with MASSACHUSETTS FINANCIAL SERVICES adding 48.7% to its position. EPS revisions for the current year (+1y) have been slightly positive over the past 30 days. The next earnings report is due August 5, adding a timing catalyst. Traders should view this downgrade as a cautionary signal from a low-accuracy firm, but the convergence with insider selling warrants attention.